Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Melanoma and Skin Cancer

Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy

Melanoma Res

Asher N, Bar-Hai N, Ben-Betzalel G, Stoff R, Grynberg S, Schachter J, Frommer-Shapira R

doi: 10.1097/CMR.0000000000000985

Melanoma and Skin Cancer

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort

Melanoma Res

Macaire C, Lefevre W, Dalac S, Montaudié H, Legoupil D, Dereure O, Dutriaux C, Leccia MT, Aubin F, Grob JJ, Saiag P, De Quatrebarbes J, Maubec E, Lesimple T, Granel-Brocard F, Mortier L, Dalle S, Lebbé C, Prod'homme C

doi: 10.1097/CMR.0000000000000973

Melanoma and Skin Cancer

Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors

Melanoma Res

Janßen S, Moufarrej A, Springer R, Häberle L, Jäger P, Antke C, Homey B, Lindhof HH

doi: 10.1097/CMR.0000000000001028

Rheumatoid Arthritis

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

Semin Arthritis Rheum

Goldman A, Galper BL, Druyan A, Grossman C, Sharif K, Shechtman L, Moshkovits Y, Lahat A, Ben-Zvi I

doi: 10.1016/j.semarthrit.2024.152461

Melanoma and Skin Cancer

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Melanoma Res

Al-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger JM

doi: 10.1097/CMR.0000000000001014

Rheumatoid Arthritis

Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials

Semin Arthritis Rheum

Pugliesi A, Oliveira DGC, Filho VAS, Machado JO, Pereira AG, Bichuette JCS, Sachetto Z, de Carvalho LSF, Bertolo MB

doi: 10.1016/j.semarthrit.2024.152563

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

EULAR 2024

Psoriatic Arthritis

Related content

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort

Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

PRO-SPIRIT: Real-world comparison of five therapies for treating patients with psoriatic arthritis